Back to today’s briefing

Story perspectives

Upadacitinib Restores Scalp Hair in Severe Alopecia Areata

8/31/2026

44 8 Full Breakdown

Summary

Story summary

U.S. researchers reported that upadacitinib regrew scalp hair in severe alopecia areata patients.
Participants received daily 15 mg or 30 mg upadacitinib or placebo in two international trials.
After 24 weeks, about half achieved at least 80% scalp hair coverage, with some achieving near-complete restoration.
The oral JAK inhibitor, originally approved for arthritis, was reported in JAMA Dermatology on August 12, 2026.

1 of 1

Story summary

U.S. researchers reported that upadacitinib regrew scalp hair in severe alopecia areata patients.
Participants received daily 15 mg or 30 mg upadacitinib or placebo in two international trials.
After 24 weeks, about half achieved at least 80% scalp hair coverage, with some achieving near-complete restoration.
The oral JAK inhibitor, originally approved for arthritis, was reported in JAMA Dermatology on August 12, 2026.